News

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patientsKANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- ...